Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets
Petros Pharmaceuticals (NASDAQ:PTPI) has received a delisting determination from Nasdaq, resulting in the suspension of trading of its common stock. Starting May 22, 2025, the company's securities will transition to trading on the OTC Markets under the ticker "PTPI". The company, which focuses on expanding consumer access through OTC drug development programs, plans to appeal the delisting decision. Fady Boctor, President and Chief Commercial Officer, noted that Petros maintains a strong cash position of over $10 million and remains committed to advancing its business plan and increasing stockholder value.
Petros Pharmaceuticals (NASDAQ:PTPI) ha ricevuto una decisione di esclusione dalla quotazione da parte di Nasdaq, con conseguente sospensione delle negoziazioni delle sue azioni ordinarie. A partire dal 22 maggio 2025, i titoli della società saranno quotati sui mercati OTC con il simbolo "PTPI". La società, che si concentra sull'ampliamento dell'accesso dei consumatori tramite programmi di sviluppo di farmaci da banco, intende presentare ricorso contro la decisione di esclusione. Fady Boctor, Presidente e Chief Commercial Officer, ha sottolineato che Petros mantiene una solida posizione di cassa di oltre 10 milioni di dollari e rimane determinata a portare avanti il proprio piano aziendale e ad aumentare il valore per gli azionisti.
Petros Pharmaceuticals (NASDAQ:PTPI) ha recibido una determinación de exclusión por parte de Nasdaq, lo que ha provocado la suspensión de la negociación de sus acciones ordinarias. A partir del 22 de mayo de 2025, los valores de la empresa pasarán a cotizar en los mercados OTC bajo el símbolo "PTPI". La compañía, que se enfoca en ampliar el acceso del consumidor a través de programas de desarrollo de medicamentos OTC, planea apelar la decisión de exclusión. Fady Boctor, presidente y director comercial, señaló que Petros mantiene una sólida posición de efectivo de más de 10 millones de dólares y sigue comprometida con avanzar en su plan de negocios y aumentar el valor para los accionistas.
Petros Pharmaceuticals (NASDAQ:PTPI)가 나스닥으로부터 상장폐지 결정을 받아 보통주 거래가 중단되었습니다. 2025년 5월 22일부터 회사의 증권은 OTC 마켓에서 "PTPI"라는 티커로 거래될 예정입니다. 소비자 접근성 확대를 위한 OTC 의약품 개발 프로그램에 주력하는 이 회사는 상장폐지 결정에 대해 항소할 계획입니다. Fady Boctor 사장 겸 최고상업책임자는 Petros가 1,000만 달러 이상의 강력한 현금 보유고를 유지하고 있으며, 사업 계획을 추진하고 주주 가치를 높이는 데 전념하고 있다고 밝혔습니다.
Petros Pharmaceuticals (NASDAQ:PTPI) a reçu une décision de radiation de la part du Nasdaq, entraînant la suspension de la négociation de ses actions ordinaires. À compter du 22 mai 2025, les titres de la société seront négociés sur les marchés OTC sous le symbole "PTPI". L'entreprise, qui se concentre sur l'élargissement de l'accès des consommateurs grâce à des programmes de développement de médicaments en vente libre, prévoit de faire appel de la décision de radiation. Fady Boctor, président et directeur commercial, a souligné que Petros dispose d'une solide trésorerie de plus de 10 millions de dollars et reste déterminée à faire avancer son plan d'affaires et à accroître la valeur pour ses actionnaires.
Petros Pharmaceuticals (NASDAQ:PTPI) hat von der Nasdaq eine Delisting-Entscheidung erhalten, die zur Aussetzung des Handels mit seinen Stammaktien führt. Ab dem 22. Mai 2025 werden die Wertpapiere des Unternehmens unter dem Tickersymbol "PTPI" an den OTC-Märkten gehandelt. Das Unternehmen, das sich auf die Erweiterung des Verbraucherzugangs durch OTC-Arzneimittelentwicklungsprogramme konzentriert, plant, gegen die Delisting-Entscheidung Berufung einzulegen. Fady Boctor, Präsident und Chief Commercial Officer, betonte, dass Petros über eine starke Liquiditätsposition von über 10 Millionen US-Dollar verfügt und weiterhin entschlossen ist, seinen Geschäftsplan voranzutreiben und den Wert für die Aktionäre zu steigern.
- Strong cash position of over $10 million
- Company plans to appeal the delisting determination
- Management remains committed to business plan execution
- Delisting from Nasdaq and transition to OTC Markets
- Potential reduced visibility and trading liquidity on OTC Markets
- Loss of institutional investor access and credibility associated with Nasdaq listing
The Company Intends to Appeal the Delisting Determination
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces that it has received a staff determination letter from the Nasdaq Stock Market, LLC ("Nasdaq"), informing the Company that Nasdaq determined to suspend trading and delist the Company's common stock from Nasdaq. At the open of trading on Thursday, May 22, 2025, Petros' securities will be suspended on Nasdaq and are expected to begin trading on the OTC Markets under the ticker "PTPI".
Fady Boctor, Petros' President and Chief Commercial Officer, commented, "We are disappointed with the delisting determination and we plan to appeal. With over
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc. is committed to the goal of becoming a leading innovator in the emerging
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based upon the Company management's assumptions, expectations, projections, intentions, and beliefs about future events. In some cases, predictive, future-tense or forward-looking words such as "intend," "develop," "goal," "plan," "predict", "may," "will," "project," "estimate," "anticipate," "believe," "expect," "continue," "potential," "opportunity," "forecast," "should," "target," "strategy" and similar expressions, whether in the negative or affirmative, that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. Such forward-looking statements are only predictions, and actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of risks and uncertainties, Petros' ability to execute on its business strategy, including its plans to develop and commercialize its proprietary Rx-to-OTC switch technology Petros' ability to comply with obligations as a public reporting company; Petros' expectations related to the Company's partnership with Innolitics; risks related to Petros' appeal of the Nasdaq delisting determination; risks related to the trading of Petros' Common Stock on the OTC Markets; risks related to Petros' ability to continue as a going concern; risks related to Petros' history of incurring significant losses; and risks related to Petros' ability to obtain regulatory approvals for, or market acceptance of, any of its products or product candidates, including its proprietary Rx-to-OTC switch technology. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in the Company's periodic reports and in other filings that the Company has filed, or may file, with the U.S. Securities and Exchange Commission (the "SEC") under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere. The Company cautions readers that the forward-looking statements included in this press release represent our beliefs, expectations, estimates and assumptions only as of the date of hereof and are not intended to give any assurance as to future results. New factors emerge from time to time, and it is not possible for us to predict all these factors. Further, the Company cannot assess the effect of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement. Accordingly, you should not unduly rely on any forward-looking statements.
The Company undertakes no obligation to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events, a change in our views or expectations or otherwise, except as required by federal securities laws.
Contacts
Investors:
CORE IR
ir@petrospharma.com
Media:
Jules Abraham
CORE IR
917-885-7378
pr@coreir.com
SOURCE: Petros Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
Why is PTPI stock being delisted from Nasdaq?
When will PTPI stock begin trading on OTC Markets?
How much cash does Petros Pharmaceuticals (PTPI) have?
What impact will the Nasdaq delisting have on PTPI shareholders?
